JP2019513725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513725A5 JP2019513725A5 JP2018552062A JP2018552062A JP2019513725A5 JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5 JP 2018552062 A JP2018552062 A JP 2018552062A JP 2018552062 A JP2018552062 A JP 2018552062A JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- binds
- immune checkpoint
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605947 | 2016-04-07 | ||
| GB1605947.9 | 2016-04-07 | ||
| PCT/EP2017/056469 WO2017174331A1 (en) | 2016-04-07 | 2017-03-17 | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513725A JP2019513725A (ja) | 2019-05-30 |
| JP2019513725A5 true JP2019513725A5 (https=) | 2020-04-23 |
| JP7325959B2 JP7325959B2 (ja) | 2023-08-15 |
Family
ID=58358618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552062A Active JP7325959B2 (ja) | 2016-04-07 | 2017-03-17 | 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190135925A1 (https=) |
| EP (1) | EP3440109B1 (https=) |
| JP (1) | JP7325959B2 (https=) |
| KR (2) | KR20190017735A (https=) |
| CN (1) | CN109476739A (https=) |
| AU (1) | AU2017247880B2 (https=) |
| BR (1) | BR112018070636A2 (https=) |
| CA (1) | CA3020204A1 (https=) |
| CL (2) | CL2018002828A1 (https=) |
| ES (1) | ES3046543T3 (https=) |
| IL (1) | IL262129B2 (https=) |
| MX (1) | MX2018012319A (https=) |
| PL (1) | PL3440109T3 (https=) |
| RU (1) | RU2759970C2 (https=) |
| WO (1) | WO2017174331A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| EP3737698A2 (en) * | 2018-01-10 | 2020-11-18 | BioInvent International AB | Novel combination and use of antibodies |
| AU2019221544B2 (en) * | 2018-02-13 | 2025-07-10 | Precision Biologics, Inc. | Methods and compositions for targeting Treg cells |
| US10752691B2 (en) * | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| WO2020028269A2 (en) * | 2018-07-30 | 2020-02-06 | Invenra Inc. | Multispecific treg binding molecules |
| WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
| ES2975410T3 (es) * | 2020-02-13 | 2024-07-05 | UCB Biopharma SRL | Anticuerpos biespecíficos que se unen a HVEM y CD9 |
| JP2023525060A (ja) * | 2020-05-14 | 2023-06-14 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ２５抗体、その抗原結合断片及びその医薬用途 |
| KR20230107641A (ko) | 2020-11-13 | 2023-07-17 | 아이바이오, 인크. | Cd25 항체 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| US20240352136A1 (en) | 2021-09-02 | 2024-10-24 | Hoffmann-La Roche Inc. | Antibodies for the treatment of aml |
| TW202336033A (zh) * | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| EP4514388A1 (en) | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024151091A1 (ko) * | 2023-01-11 | 2024-07-18 | 한국과학기술원 | 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| WO2024165454A1 (en) | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Combination therapy and uses thereof |
| TW202444760A (zh) | 2023-03-29 | 2024-11-16 | 日商第一三共股份有限公司 | 抗ｃｄ２５抗體及抗ｃｄ２５抗體－藥物複合體 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7438907B2 (en) * | 2002-11-15 | 2008-10-21 | Genmab A/S | Human monoclonal antibodies against CD25 |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| US20090304711A1 (en) * | 2006-09-20 | 2009-12-10 | Drew Pardoll | Combinatorial Therapy of Cancer and Infectious Diseases with Anti-B7-H1 Antibodies |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| KR20190017735A (ko) | 2016-04-07 | 2019-02-20 | 캔써 리서치 테크놀로지 리미티드 | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| US10752691B2 (en) * | 2018-03-13 | 2020-08-25 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| EP4514388A1 (en) * | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
-
2017
- 2017-03-17 KR KR1020187032183A patent/KR20190017735A/ko not_active Ceased
- 2017-03-17 US US16/091,350 patent/US20190135925A1/en not_active Abandoned
- 2017-03-17 PL PL17711664.7T patent/PL3440109T3/pl unknown
- 2017-03-17 EP EP17711664.7A patent/EP3440109B1/en active Active
- 2017-03-17 ES ES17711664T patent/ES3046543T3/es active Active
- 2017-03-17 IL IL262129A patent/IL262129B2/en unknown
- 2017-03-17 MX MX2018012319A patent/MX2018012319A/es unknown
- 2017-03-17 WO PCT/EP2017/056469 patent/WO2017174331A1/en not_active Ceased
- 2017-03-17 JP JP2018552062A patent/JP7325959B2/ja active Active
- 2017-03-17 AU AU2017247880A patent/AU2017247880B2/en active Active
- 2017-03-17 KR KR1020227006876A patent/KR20220032642A/ko not_active Ceased
- 2017-03-17 RU RU2018135247A patent/RU2759970C2/ru active
- 2017-03-17 CN CN201780022552.4A patent/CN109476739A/zh active Pending
- 2017-03-17 BR BR112018070636-1A patent/BR112018070636A2/pt not_active Application Discontinuation
- 2017-03-17 CA CA3020204A patent/CA3020204A1/en active Pending
-
2018
- 2018-10-04 CL CL2018002828A patent/CL2018002828A1/es unknown
-
2019
- 2019-11-29 CL CL2019003498A patent/CL2019003498A1/es unknown
-
2022
- 2022-03-28 US US17/706,028 patent/US20230265200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513725A5 (https=) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2020514363A5 (https=) | ||
| US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019500891A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2019500892A5 (https=) | ||
| JP2020514363A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| JP2018520657A5 (https=) | ||
| KR20160037989A (ko) | 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합 | |
| IL263611A (en) | Antibodies specific to PD-L1 and methods of using them | |
| JP2017537892A5 (https=) | ||
| JP2019518721A5 (https=) | ||
| JP2020502147A5 (https=) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2018528776A5 (https=) | ||
| CN111542544A (zh) | 用于治疗癌症的免疫刺激性激动性抗体 | |
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2021520201A5 (https=) | ||
| JP2023543896A5 (https=) | ||
| JP2020528765A5 (https=) | ||
| JP2021523949A5 (https=) |